10-Q: Amarin Reports Q1 2025 Financial Results: Revenue Declines Amidst Generic Competition

Amarin Corporation plc reports a net loss of $15.7 million for Q1 2025, with product revenue declining due to generic competition in the U.S.

Summary

• Amarin Corporation plc reported a net loss of $15.7 million for the three months ended March 31, 2025, compared to a net loss of $9.95 million for the same period in 2024.
• Total revenue decreased by 26% to $42.0 million, primarily due to a decline in U.S. product revenue.
• U.S. product revenue decreased by 26% to $35.7 million, attributed to lower net selling prices and decreased volume due to generic competition and the loss of a large PBM.
• Europe product revenue increased to $5.4 million from $1.9 million in the prior year.
• Licensing and royalty revenue decreased by 28% to $1.0 million.
• Cost of goods sold decreased by 31% to $16.9 million.
• Selling, general, and administrative expenses decreased by 8% to $36.6 million.
• Research and development expenses decreased by 5% to $5.3 million.
• The company had cash and short-term investments of $281.8 million as of March 31, 2025.
• The company believes its cash and short-term investments will be sufficient to fund projected operations for at least one year.
• The company implemented an ADS ratio change, effective April 11, 2025, from one ADS representing one Ordinary Share to one ADS representing 20 Ordinary Shares.
• The company regained compliance with Nasdaq listing requirements on April 29, 2025.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the revenue decline and net loss, but the company has sufficient cash reserves and is taking steps to address the challenges.

Positives

• Europe product revenue increased to $5.4 million.
• The company had cash and short-term investments of $281.8 million as of March 31, 2025.
• The company believes its cash and short-term investments will be sufficient to fund projected operations for at least one year.
• The company regained compliance with Nasdaq listing requirements on April 29, 2025.

Negatives

• Amarin's Q1 2025 net loss was $15.7 million, compared to a $9.95 million loss in Q1 2024.
• Total revenue decreased by 26% to $42.0 million due to generic competition in the U.S.
• U.S. product revenue decreased by 26% to $35.7 million.
• Licensing and royalty revenue decreased by 28% to $1.0 million.
• The company's share of the icosapent ethyl market in the U.S. decreased to approximately 42%.

Risks

• Generic competition in the U.S. continues to impact revenue and market share.
• The company's future performance is subject to risks related to commercializing VASCEPA and VAZKEPA, capital resources, clinical programs, regulatory filings, and patent protection.
• Tariffs, trade sanctions, or similar government actions could adversely affect the business.
• Failure to maintain compliance with Nasdaq listing requirements could result in delisting.
• The company has incurred annual operating losses since its inception and has an accumulated deficit of $1.7 billion as of March 31, 2025.

Future Outlook

The company will continue to focus on getting VASCEPA to as many patients as possible by continuing to advance pricing and reimbursement and licensing activities to drive access in remaining geographies as well as being the market leader in the U.S.

Management Comments

• Despite the generic competition in the U.S., we remain confident that the global patient need for VASCEPA is high.
• In 2025, we will continue to focus on getting VASCEPA to as many patients as possible by continuing to advance our pricing and reimbursement and licensing activities to drive access in remaining geographies as well as being the market leader in the U.S.
• We are focused on getting VASCEPA to as many patients as possible by continuing to advance our pricing and reimbursement and licensing activities to drive access in remaining geographies, as well as advancing regulatory filings internationally.
• We will continue to evaluate all of our spending commitments and priorities based on this focus.

Industry Context

The report highlights the impact of generic competition on Amarin's U.S. revenue, reflecting a broader trend in the pharmaceutical industry where branded drugs face revenue decline upon patent expiration and subsequent generic entry. The company's focus on international markets and partnerships aligns with strategies employed by other pharmaceutical companies to diversify revenue streams and mitigate risks associated with market-specific challenges.

Comparison to Industry Standards

• Amarin's experience with generic competition mirrors that of other pharmaceutical companies facing patent expirations, such as Pfizer with Lipitor and Merck with Singulair.
• The decline in U.S. revenue due to generic entry is a common industry phenomenon, with companies often experiencing a significant drop in sales within the first year of generic availability.
• Amarin's focus on expanding into European and other international markets is a strategy similar to that of companies like Novartis and Sanofi, which have diversified their revenue streams to mitigate risks in specific regions.
• The company's efforts to secure pricing and reimbursement in European countries are consistent with the challenges faced by other pharmaceutical companies in navigating the complex healthcare systems and regulatory landscapes in Europe.
• The company's reliance on partnerships for commercialization in certain regions is a common practice in the pharmaceutical industry, similar to arrangements between companies like AstraZeneca and Daiichi Sankyo.

Legal Proceedings

• Amarin is named as a defendant in six antitrust class action lawsuits in the District Court for the District of New Jersey.
• In June 2020, the Company received a civil investigative demand, or CID, from the U.S. Department of Justice, or the DOJ, informing Amarin that the DOJ is investigating whether aspects of its promotional speaker programs and copayment waiver program during the period going back to January 1, 2015, violated the U.S. Anti-Kickback Statute and the U.S. Civil False Claims Act, in relation to the sale and marketing of VASCEPA by the Company and its previous co-marketing partner, Kowa Pharmaceuticals America, Inc.
• On October 21, 2021, a purported investor in the Companys publicly traded securities filed a putative class action lawsuit against the Company, the former chief executive officer and the former chief financial officer in the U.S. District Court for the District of New Jersey, Vincent Dang v. Amarin Corporation plc, John F. Thero and Michael W. Kalb , No. 1:21-cv-19212 (D.N.J. Oct. 21, 2021).
• On March 29, 2023, purported investors in the Companys publicly traded securities filed a derivative lawsuit, naming as defendants the Companys former general counsel, the Companys trial counsel for the ANDA litigation, and the Company as nominal defendant, in the Superior Court of New Jersey, Law Division, Monmouth County, captioned Anne Abramson, John Lissandrello, Georgette Appiano, and Andrew Bondarowicz v. Amarin Corporation plc, Covington & Burling, LLP, Joseph T. Kennedy, and John Does A-Z , No. MON-L-000984-23 (N.J. Super. Ct. Law Div. Mar. 29, 2023).
• On November 30, 2020, the Company filed a patent infringement lawsuit against Hikma for making, selling, offering to sell, and importing generic icosapent ethyl capsules in and into the U.S. in a manner that the Company alleges induced the infringement of patents covering the use of VASCEPA to reduce specified CV risk.
• On March 31, 2023, the Companys former chief executive officer, Karim Mikhail, filed a complaint against the Company and certain of its affiliates in the Superior Court of New Jersey, Law Division Somerset County, captioned Mikhail v. Amarin Corporation, plc (Docket No. SOM-L-000366-23), concerning Mr. Mikhails alleged constructive termination from the Company.

Stakeholder Impact

• Shareholders: The decrease in revenue and net loss may negatively impact shareholder value.
• Employees: Cost optimization initiatives may lead to workforce reductions or changes in compensation.
• Customers: The availability and pricing of VASCEPA may be affected by generic competition.
• Suppliers: The company is negotiating with contract suppliers to align supply arrangements with current and future global market demand, which may impact supplier relationships.
• Patients: The company is focused on getting VASCEPA to as many patients as possible.

Next Steps

• Continue to advance pricing and reimbursement and licensing activities to drive access in remaining geographies.
• Advance regulatory filings internationally.
• Evaluate all spending commitments and priorities.

Key Dates

Keywords

VASCEPA, VAZKEPA, Amarin, Revenue, Net Loss, Generic Competition, Cardiovascular Risk, Icosapent Ethyl, REDUCE-IT, Financial Results